Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Capital Expenditures (2021 - 2025)

Biofrontera (BFRI) has 5 years of Capital Expenditures data on record, last reported at -$1000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures changed N/A year-over-year to -$1000.0; the TTM value through Sep 2025 reached $4000.0, changed N/A, while the annual FY2024 figure was $10000.0, 100.0% up from the prior year.
  • Capital Expenditures reached -$1000.0 in Q3 2025 per BFRI's latest filing, down from $1000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $57000.0 in Q1 2024 and bottomed at -$48000.0 in Q2 2024.
  • Average Capital Expenditures over 5 years is $4571.4, with a median of $1000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: tumbled 1000.0% in 2023, then soared 307.14% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $9000.0 in 2021, then crashed by 88.89% to $1000.0 in 2022, then crashed by 1000.0% to -$9000.0 in 2023, then surged by 111.11% to $1000.0 in 2024, then plummeted by 200.0% to -$1000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$1000.0 in Q3 2025, $1000.0 in Q2 2025, and $3000.0 in Q1 2025.